Pharma industry set for bumper 2015
January 5, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2015, FDA, bumper, harvoni, opdivo, pharma, sovaldi
Industry analysts predict 2015 will be another year of growth for the pharma, after approvals of new drugs soared to …
Medical publishing: can we rely on it?
January 5, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Les Rose, csr, journals, medical publishing, peer, publishing, transparency
The explosive proliferation of journals suggests that medical publishing is an attractive business. But it’s not without its critics, as …
New CFO for Echo Therapeutics
January 5, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing alan schoenbart, echo therapeutics
US medical device firm Echo Therapeutics has appointed Alan Schoenbart as its chief financial officer.Schoenbart who has more than 30 …
Novo Nordisk obesity drug gets FDA nod
December 24, 2014Sales and Marketing FDA, Novo Nordisk, Victoza, diabetes, liraglutide, saxenda
The US Food and Drug Administration has shown Novo Nordisk’s obesity drug Saxenda the green light to aid chronic weight …
NHS plans bashed over cancer and heart disease
December 24, 2014Research and Development, Sales and Marketing Cancer, England, NHS, Simon Stevens, funding, heart
Hundreds of healthcare experts have signed an open letter to NHS chief executive Simon Stevens calling for him to scrap …
Actavis hires senior head from PwC
December 24, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Jonathon Kellerman, pwC
Jonathon Kellerman has joined Ireland-based speciality pharma firm Actavis as its executive vice president and global chief compliance officer. Reporting …
NICE rejects Takeda Crohn’s disease drug
December 23, 2014Sales and Marketing Crohn’s disease, Entyvio, NHS, NICE, Takeda, crohn's disease, vedolizumab
Takeda has seen its treatment for people with Crohn’s disease Entyvio rejected by NICE in an initial appraisal. The healthcare …
EMA ramps up adaptive pathways pilot
December 23, 2014Manufacturing and Production, Research and Development, Sales and Marketing EMA, adaptive pathways, drugs, regulator
Six medicines have been selected to move to the next stage of the EMA’s adaptive pathways pilot project, to explore …
New hope through Ebola vaccine trial
December 23, 2014Research and Development, Sales and Marketing Africa, Ebola, GAVI, GSK, US, marburg, uganda
A report in the Lancet medical journal has highlighted a treatment found to be well-tolerated in healthy Ugandan adults during …
New chairman for Egenix
December 23, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing egenix, lionel goldfrank
Lionel Goldfrank has been elected to sit on the board of the US-based biotech firm Egenix. Goldfrank is to succeed Donald …
Cubist boosts antibiotics market presence
December 22, 2014Sales and Marketing Antibiotics, Zerbaxa, antimicrobial resistance, bacteria, cubist, infections, infectious diseases
Cubist has followed-up its successful European approval for a new antibiotic by winning an endorsement by the US FDA. The …
Lilly to market stomach cancer drug in Europe
December 22, 2014Sales and Marketing Eli Lilly, Europe, FDA, US, cyramza, ramucirumab, stomach cancer
Eli Lilly has been granted permission by the European Commission to market Cyramza in Europe. Lilly’s Cyramza (ramucirumab) is the …
Abbvie Hep C drug gains FDA approval
December 22, 2014Sales and Marketing AbbVie, FDA, Gilead, Viekira Pak, dasabuvir, harvoni, hepatitis, hepatits C
Abbvie has gained sign-off for its rival treatment to challenge Gilead’s dominance of the growing market for new hepatitis C …
Chiesi gets first-ever European stem cell nod
December 19, 2014Sales and Marketing Chiese, Chiesi, EMA, Holoclar, LSCD, MHRA, Stem cells, orexigen
Chiesi has received the first approval for an advanced therapy medicinal product containing stem cells for use in Europe. The …
Visions for the future: FT pharma and biotech event
December 19, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2020, ABPI, Deloitte, Medidata, Whitehead, financial ties, freeman, ft pharma
The FT Global Pharmaceutical and Biotechnology Conference held in London recently asked: “What will the life science company of the …
Merck acquires Swiss firm OncoEthix
December 19, 2014Sales and Marketing Cancer, FDA, Merck, OTX015, cubist, keytruda, oncoethix, pembrolizumab
Hot on the heals of its Cubist buyout Merck has confirmed the acquisition of OncoEthix, a Swiss based firm which …
Roche dealt with two late-stage blows
December 19, 2014Sales and Marketing Alzheimer's, Alzheimer’s, Cancer, Kadcyla, Perjeta, Roche, Xeloda, trastuzumab emtansine
Swiss giant Roche’s breast cancer treatment Kadcyla has failed to meet its primary endpoint and its investigational Alzheimer’s treatment trial …
GSK shingles vaccine on form
December 19, 2014Sales and Marketing GSK, HZ/su, Merck, Vaccine, Zostavax, shingles
GlaxoSmithKline will be celebrating following the successful Phase III study of its shingles vaccine HZ/su that has met its primary …
NHS not au fait with mobile-savvy patients
December 19, 2014Medical Communications, Sales and Marketing NHS, app, digital, health, mobile, smartphones, wearables
The NHS is failing to keep up with its digital generation of patients, a recent study has found. Despite a …
Takeda takes senior head from Sanofi
December 19, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, Takeda, andrew plump
Dr Andrew Plump will be joining Takeda in February from Sanofi to lead its global R&D operations as chief medical …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
